Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Mimedx (MDXG) over the last 16 years, with Q3 2025 value amounting to $4.9 million.

  • Mimedx's Share-based Compensation rose 2914.15% to $4.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.6 million, marking a year-over-year increase of 1202.94%. This contributed to the annual value of $16.9 million for FY2024, which is 15.33% down from last year.
  • According to the latest figures from Q3 2025, Mimedx's Share-based Compensation is $4.9 million, which was up 2914.15% from $4.8 million recorded in Q2 2025.
  • Mimedx's 5-year Share-based Compensation high stood at $4.9 million for Q3 2025, and its period low was $530000.0 during Q4 2022.
  • In the last 5 years, Mimedx's Share-based Compensation had a median value of $4.1 million in 2021 and averaged $3.8 million.
  • As far as peak fluctuations go, Mimedx's Share-based Compensation plummeted by 8257.15% in 2022, and later soared by 72754.72% in 2023.
  • Over the past 5 years, Mimedx's Share-based Compensation (Quarter) stood at $3.0 million in 2021, then plummeted by 82.57% to $530000.0 in 2022, then soared by 727.55% to $4.4 million in 2023, then increased by 7.0% to $4.7 million in 2024, then increased by 4.82% to $4.9 million in 2025.
  • Its last three reported values are $4.9 million in Q3 2025, $4.8 million for Q2 2025, and $4.3 million during Q1 2025.